L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:515506 HCAPLUS

DOCUMENT NUMBER: 141:71453

TITLE: Preparation of anthranilic acid amide derivatives as

neoplastic inhibitors

INVENTOR(S): Bold, Guido; Furet, Pascal; Manley, Paul William

PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	PATENT NO.					KIND		DATE		APPLICATION NO.					DATE			
WO	√O 2004052884				A1		20040624		WO 2003-EP14086						20031211			
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,	
		GE,	GH,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	
		•		•	•		MK,	•	•					•	•	•		
							SK,			,			•					
			YU,			,	,	,	,	,	,	,	,	,	,	,	,	
	RW:					K7.	MD,	RU.	TJ.	TM.	AT.	BE.	BG.	CH.	CY.	C7.	DE.	
	•						GB,											
				•	,	,	02,	011,	110,	,	,	,	110,	,	,	1.0,	22,	
$C\Delta$	SI, SK, TR				Δ1	A1 20040624 CA 2003-2506164								20031211				
	AU 2003294834																	
	EP 1572686																	
Li C							ES,											
	Κ.																	
DD	2002						RO,											
BK	BR 2003017292				A		2005	1108		BK Z	003-	1/29	4045		2	0031	Z I I	
CN	CN 1720244 JP 2006511518				A 20060111			CN 2003-80104845						20031211				
JP	JP 2006511518				Т		20060406			JP 2004-558075					2	0031	211	
	US 20060128684				A1		2006	0615										
PRIORIT	PRIORITY APPLN. INFO.:															0021		
										WO 2	003-	EP14	086		W 2	0031	211	
OTHER S	OTHER SOURCE(S):				MAR:	PAT	141:	71453	3									
GI																		

AB The title compds. I [wherein R and R0 = independently H, halo, (un)substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, etc.; R1 = H, halo, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, OCF3, OCH2CF3, OCH2CH2CF3, or OCH2CH2CF3; R2 = perfluoroalkyl; R3 = H or halo; X = OH, alkoxy, alkylthio, imino, alkylimino, halo, etc.; Z = N or CH] or salts, N-oxides, or tautomers thereof are prepared as neoplastic inhibitors for the treatment of human or animal body. For example, the compound II was prepared in a multi-step synthesis. Formulations containing I as an active ingredient were also described.

IT 709045-02-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate, reactant; preparation of anthranilic acid amide derivs. as neoplastic inhibitors)

RN 709045-02-3 HCAPLUS

CN Benzamide, 2-[[(6-methoxy-5-phenyl-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

IT 709045-03-4P 709045-42-1P 709045-43-2P
 709045-44-3P 709045-45-4P 709045-48-7P
 709045-49-8P 709045-50-1P 709045-51-2P
 709045-52-3P 709045-53-4P 709045-54-5P
 709045-55-6P 709045-56-7P 709045-57-8P
 709045-58-9P 709045-59-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of anthranilic acid amide derivs. as neoplastic inhibitors)

RN 709045-03-4 HCAPLUS

CN Benzamide, 2-[[(1,6-dihydro-6-oxo-5-phenyl-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-42-1 HCAPLUS

CN Benzamide, 2-[[[6-methoxy-5-(3-thienyl)-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-43-2 HCAPLUS

CN Benzamide, 2-[[[1,6-dihydro-6-oxo-5-(3-thienyl)-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-44-3 HCAPLUS

CN Benzamide, 2-[[(5-[1,1'-biphenyl]-3-yl-6-methoxy-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-45-4 HCAPLUS

CN Benzamide, 2-[[(5-[1,1'-biphenyl]-3-yl-1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-48-7 HCAPLUS

CN Benzamide, 2-[[[5-[3-(acetylamino)phenyl]-6-methoxy-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-49-8 HCAPLUS

CN Benzamide, 2-[[[5-[3-(acetylamino)phenyl]-1,6-dihydro-6-oxo-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-50-1 HCAPLUS

CN Benzamide, 2-[[[5-(4-formylphenyl)-6-methoxy-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-51-2 HCAPLUS

CN Benzamide, 2-[[[5-(4-formylphenyl)-1,6-dihydro-6-oxo-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-52-3 HCAPLUS

CN Benzamide, 2-[[[6-methoxy-5-[3-(trifluoromethyl)phenyl]-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-53-4 HCAPLUS

CN Benzamide, 2-[[[1,6-dihydro-6-oxo-5-[3-(trifluoromethyl)phenyl]-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-54-5 HCAPLUS

CN Benzamide, 2-[[(2'-methoxy[2,3'-bipyridin]-5'-yl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

MeO
$$CH_2-NH$$
 $O=C$ F_3C NH

RN 709045-55-6 HCAPLUS

CN Benzamide, 2-[[(1',2'-dihydro-2'-oxo[2,3'-bipyridin]-5'-yl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-56-7 HCAPLUS

CN Benzamide, 2-[[[5-(2-furanyl)-6-methoxy-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-57-8 HCAPLUS

CN Benzamide, 2-[[[5-(2-furanyl)-1,6-dihydro-6-oxo-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-58-9 HCAPLUS

CN Benzamide, 2-[[[6-methoxy-5-(2-thiazolyl)-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 709045-59-0 HCAPLUS
CN Benzamide, 2-[[[1,6-dihydro-6-oxo-5-(2-thiazolyl)-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)